目的评价长春祈健生物制品有限公司生产的冻干水痘減毒活疫苗(Varicella Attenuated Live Vaccine,Freeze-dried;VarV-Fd)的安全性及流行病学效果。方法选择未患过水痘、流行性腮腺炎等传染病,无接种禁忌证,过去未接种过水痘、麻疹、流...目的评价长春祈健生物制品有限公司生产的冻干水痘減毒活疫苗(Varicella Attenuated Live Vaccine,Freeze-dried;VarV-Fd)的安全性及流行病学效果。方法选择未患过水痘、流行性腮腺炎等传染病,无接种禁忌证,过去未接种过水痘、麻疹、流行性腮腺炎减毒活疫苗,且近一个月内未接种过其他预防性生物制品,年龄在3～6岁的托幼机构儿童和年龄在7～9岁在校小学生5192人作为观察对象。按照随机双盲对照临床试验原则,将入选的观察对象分为试验组和对照组,其中试验组2593人接种VarV-Fd,对照组2599人接种麻疹-流行性腮腺炎联合减毒活疫苗。结果经追踪随访,试验组水痘发病率为2.70‰,对照组为14.24‰,经Fisher's确切概率法检验,差异有统计学意义(P<0.001),VarV-Fd的保护率为81.04%,95%可信区间为65.75%～96.33%。结论长春祈健生物制品有限公司生产的VarV-Fd具有良好流行病学保护效果。展开更多
目的评价冻干水痘减毒活疫苗(Varicella Freeze-dried Attenuated Live Vaccine,VarV)的现场流行病学效果和疫苗安全性。方法选择近3年未发生过水痘流行、无水痘患病史、未接种过VarV的小学生和托幼机构儿童作为观察对象。采取随机、盲...目的评价冻干水痘减毒活疫苗(Varicella Freeze-dried Attenuated Live Vaccine,VarV)的现场流行病学效果和疫苗安全性。方法选择近3年未发生过水痘流行、无水痘患病史、未接种过VarV的小学生和托幼机构儿童作为观察对象。采取随机、盲法、对照的方法,将入选的观察对象分成试验组2476人,接种VarV;对照组2534人,接种流行性腮腺炎减毒活疫苗。结果经追踪随访,水痘发病率试验组为0.8‰,对照组为8.7‰。根据二项分布概率法检验,差异有非常显著的统计学意义(B.P=0.000017)。疫苗效果(Vaccine Efficacy,VE)为90.8%,VE95%可信限下限为88.8%。结论VarV具有良好的现场流行病学保护效果和安全性。展开更多
目的了解佳木斯市2004-2017年肾综合征出血热(hemorrhagic fever with renal syndrome,HFRS)流行病学特征,评价HFRS疫苗防控效果,并为预防控制提供科学依据。方法对佳木斯市2004-2017年HFRS网络直报资料进行描述性分析,率的比较采用卡...目的了解佳木斯市2004-2017年肾综合征出血热(hemorrhagic fever with renal syndrome,HFRS)流行病学特征,评价HFRS疫苗防控效果,并为预防控制提供科学依据。方法对佳木斯市2004-2017年HFRS网络直报资料进行描述性分析,率的比较采用卡方检验。结果佳木斯市2004-2017年报告HFRS病例5318例,年平均发病率为15.33/10万,不同年份的平均发病率差异有统计学意义(χ^2=1856.94,P<0.05)。HFRS发病具有明显的季节特征;病例主要以青壮年男性为主;职业以农民为主,占69.76%;男女性别比为3.64∶1,男性平均发病率高于女性,差异有统计学意义(χ^2=1617.99,P<0.05);HFRS疫苗接种后发病率逐年下降。结论HFRS防控重点人群为农民,此外,工人、学生、离退休人员、家务等职业人群也应加强防护;疫苗接种对防控HFRS效果明显,建议提高45岁以上人群疫苗接种覆盖率。展开更多
In this paper we provide different types of approach in mathematical biology about infection disease and understanding the dynamic of epidemic mathematical models specially in COVID-19 disease which first outbroke in ...In this paper we provide different types of approach in mathematical biology about infection disease and understanding the dynamic of epidemic mathematical models specially in COVID-19 disease which first outbroke in China and fast spread around the world. We work in the connection between the mathematical models and the solution analytically and numerically. At first, we emphasize the Susceptible-Infectious-Recovered (SIR) models’ extension for policy significance. Then, we found the improved SIER model done by research. In third section, we examine the improved model when an appropriate vaccine has been found, we introduce the model of SIR with vaccine term which ends up with discussion and conclusion about the effect of vaccinate. The comprehension of COVID-19 transmission methods, structures, and characteristics is greatly aided by these mathematical models analytically and numerically.展开更多
目的评价冻干水痘减毒活疫苗(Varicella Freeze-dried Attenuated Live Vaccine,VarV)的现场流行病学效果和疫苗安全性。方法选择未发生过水痘流行、无水痘患病史、未接种过VarV的小学生和托幼机构儿童作为观察对象,采取随机、盲法、对...目的评价冻干水痘减毒活疫苗(Varicella Freeze-dried Attenuated Live Vaccine,VarV)的现场流行病学效果和疫苗安全性。方法选择未发生过水痘流行、无水痘患病史、未接种过VarV的小学生和托幼机构儿童作为观察对象,采取随机、盲法、对照的方法 ,将入选的观察对象分成试验组2588人,接种VarV;对照组2598人,接种流行性腮腺炎减毒活疫苗。结果经追踪随访,试验组发病率为2.70‰,对照组为14.63‰。结论具有良好的现场流行病学保护效果和安全性。展开更多
文摘目的评价长春祈健生物制品有限公司生产的冻干水痘減毒活疫苗(Varicella Attenuated Live Vaccine,Freeze-dried;VarV-Fd)的安全性及流行病学效果。方法选择未患过水痘、流行性腮腺炎等传染病,无接种禁忌证,过去未接种过水痘、麻疹、流行性腮腺炎减毒活疫苗,且近一个月内未接种过其他预防性生物制品,年龄在3～6岁的托幼机构儿童和年龄在7～9岁在校小学生5192人作为观察对象。按照随机双盲对照临床试验原则,将入选的观察对象分为试验组和对照组,其中试验组2593人接种VarV-Fd,对照组2599人接种麻疹-流行性腮腺炎联合减毒活疫苗。结果经追踪随访,试验组水痘发病率为2.70‰,对照组为14.24‰,经Fisher's确切概率法检验,差异有统计学意义(P<0.001),VarV-Fd的保护率为81.04%,95%可信区间为65.75%～96.33%。结论长春祈健生物制品有限公司生产的VarV-Fd具有良好流行病学保护效果。
文摘目的了解佳木斯市2004-2017年肾综合征出血热(hemorrhagic fever with renal syndrome,HFRS)流行病学特征,评价HFRS疫苗防控效果,并为预防控制提供科学依据。方法对佳木斯市2004-2017年HFRS网络直报资料进行描述性分析,率的比较采用卡方检验。结果佳木斯市2004-2017年报告HFRS病例5318例,年平均发病率为15.33/10万,不同年份的平均发病率差异有统计学意义(χ^2=1856.94,P<0.05)。HFRS发病具有明显的季节特征;病例主要以青壮年男性为主;职业以农民为主,占69.76%;男女性别比为3.64∶1,男性平均发病率高于女性,差异有统计学意义(χ^2=1617.99,P<0.05);HFRS疫苗接种后发病率逐年下降。结论HFRS防控重点人群为农民,此外,工人、学生、离退休人员、家务等职业人群也应加强防护;疫苗接种对防控HFRS效果明显,建议提高45岁以上人群疫苗接种覆盖率。
文摘In this paper we provide different types of approach in mathematical biology about infection disease and understanding the dynamic of epidemic mathematical models specially in COVID-19 disease which first outbroke in China and fast spread around the world. We work in the connection between the mathematical models and the solution analytically and numerically. At first, we emphasize the Susceptible-Infectious-Recovered (SIR) models’ extension for policy significance. Then, we found the improved SIER model done by research. In third section, we examine the improved model when an appropriate vaccine has been found, we introduce the model of SIR with vaccine term which ends up with discussion and conclusion about the effect of vaccinate. The comprehension of COVID-19 transmission methods, structures, and characteristics is greatly aided by these mathematical models analytically and numerically.
